Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRAIN-AHF
NCT06166654Phase 3Recruiting
- Start
- Sep 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Acetazolamide, Metolazone and Placebo (3 arms). Primary endpoint: Days alive and out of hospital at 30 days. Started Sep 2024; status: recruiting.
02
Drugs
acetazolamidemetolazone
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT06166654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06166654.